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ABSTRACT
DIETARY OLIGOSACCHARIDES MODULATE BIFIDOBACTERIAL
PRODUCTION OF THE NEUROTRANSMITTER 𝜸-AMINOBUTYRIC ACID

SEPTEMBER 2020

MICHELLE R. ROZYCKI, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST

Directed by: Dr. David A. Sela
Bifidobacteria are the predominant members of the infant gut, colonize adults to a
lesser extent, and are recognized as beneficial microbes. Various bifidobacterial species
produce 𝛾-aminobutryic acid (GABA), the chief inhibitory neurotransmitter in the
mammalian central nervous system. It is postulated that in order to produce GABA, the
bifidobacterial genome must contain the gadB and gadC genes which encode a glutamate
decarboxylase and a glutamate/GABA antiporter, respectively. Once exported by GadC,
GABA is absorbed and transported systemically throughout the host. We hypothesize that
specific dietary oligosaccharides will modulate bifidobacterial production of GABA due
to varying intracellular concentrations of glutamate. To test this, 33 bifidobacterial strains
were screened for GABA production via reverse phase HPLC. Interestingly, 10 strains
contained both gadB and gadC genes, but only 8 strains produced detectable GABA in
vitro. To further elucidate the extrinsic factors influencing GABA production, strains were
subjected to different dietary components. Specifically, lactose and the dietary
iv

oligosaccharide FOS were evaluated for the ability to promote biosynthesis of intracellular
glutamate and thus potentially GABA. Understanding the relationship between diet,
bifidobacterial physiology, and GABA production may inform dietary interventions to
modulate this neurotransmitter in vivo.
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CHAPTER 1
INTRODUCTION
Bifidobacteria are the predominant members of the infant gut microbiome
and are essential for establishing a stable early microbial community. Bifidobacterial
colonization of the infant gut is mediated by the fermentation of human milk
oligosaccharides (HMOs)1-5. Although less abundant in adults, bifidobacteria are an
important member of the adult gut microbiome as they ferment host-indigestible
oligosaccharides. Host consumption of oligosaccharides, including fructooligosaccharides
(FOS), galactooligosaccharides (GOS), and arabinoxylan oligosaccharides (AXOS) have
been demonstrated to promote the growth of bifidobacteria in vivo and in vitro6-11. Analysis
of the Bifidobacterium pan-genome revealed 13.7% of Bifidobacterium-specific clusters of
orthologous genes (BifCOGs) belonged to the carbohydrate metabolism functional family
of proteins, which include glycosyl hydrolases (GH), glycosyl transferases (GT) and
carbohydrate esterases (CE). Carbohydrate-active enzyme family GH13, enzymes
characterized by their ability to degrade plant oligosaccharides, are commonly found in
bifidobacteria genomes12.
The importance of oligosaccharides extends further than increasing bifidobacterial
populations, as there is a correlation between consumption of oligosaccharides and exertion
of antidepressant and anxiolytic effects on the host 13-16. Male mice exposed to chronic
stress that consumed a combination of FOS+GOS had reduced levels of stress-induced
corticosterone, as well as modified short-chain fatty acid (SCFA) concentrations in the
gut13. GOS was supplemented in a human intervention study with female adolescents over
a 4-week period. Reductions in anxiety were reported and microbial analysis of stool
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samples revealed an increased abundance of Bifidobacterium spp., compared to the placebo
group14. Physiological effects of plant oligosaccharide metabolism could be induced by a
variety of bioactive metabolites, including 𝛾-aminobutyric acid (GABA), produced by gut
microbiota that interact with the gut-brain axis (GBA). The GBA is a bidirectional
connection between the central and enteric nervous system. It has been suggested that
molecules produced by gut microbiota, like GABA, have the potential to interact with the
GBA, sending signals directly to the brain17,18.
GABA is a bioactive non-protein amino acid and the primary inhibitory
neurotransmitter of the central nervous system (CNS). It primarily interacts with GABAA
and GABAB receptors in the host to induce hyperpolarization, which inhibit action
potentials19-21. If GABA production decreases and GABA receptors interact with other
neuroactive compounds, neurological disorders can arise. GABA pathophysiology has
been implicated in anxiety disorders, depression and autism spectrum disorder22-26. GABA
is primarily synthesized from glutamate by a glutamate decarboxylase (GAD, EC 4.1.1.15)
in animals and bacteria. Gad1 and Gad2 are responsible for GABA synthesis in the brain27
while GadA and/or GadB synthesize GABA in bacteria. Along with a glutamate
decarboxylase, bacteria also possess a glutamate/GABA antiporter (GadC) that selectively
transports glutamate into the cell and exports GABA 28-31. Some pathogenic bacteria,
including Escherichia coli and Listeria monocytogenes, have adapted gad operons as acid
resistance (AR) systems, protecting the organism from the acidic environment of the
digestive system32-35. E. coli possess multiple gad genes, as a part of an acid resistance
system. They possess gadA, gadB, gadC and gadE, the primary regular of the glutamatemediated acid resistance system33. GABA-producing AR systems are not exclusive to
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pathogens; strains of Lactobacillus spp. possess Gad-mediated AR systems as well29,36,37.
Bifidobacterium spp. production of GABA is not part of an AR system, as they only possess
gadB and gadC genes in their gad operon30.
Presence of gad genes and production of GABA by Bifidobacterium spp. are not
inherent to the genus. We identified 6 species of bifidobacteria (Bifidobacterium
adolescentis, Bifidobacterium angulatum, Bifidobacterium dentium, Bifidobacterium
merycicum, Bifidobacterium moukalabense, Bifidobacterium ruminantium) through
NCBI/BLASTp that possess both gadB and gadC genes. Previous publications report
GABA-producing bifidobacteria which include B. adolescentis, B. angulatum, B. dentium
and Bifidobacterium longum subsp. infantis30,38,39. Moreover, strains of B. adolescentis, B.
angulatum, and B. dentium ferment FOS and GOS in vitro6,10,40,41. Fermented
oligosaccharides are cleaved into monosaccharides (including glucose and galactose) that
can be metabolized in the fructose-6-phosphate phosphoketolase pathway (F6PPK).
Intermediates of the pathway are proposed to be involved in the biosynthesis of various
amino acids, including glutamate42. We hypothesize that dietary oligosaccharides will
modulate bifidobacterial production of GABA due to varying intracellular concentrations
of glutamate. Understanding the relationship between diet, bifidobacterial physiology, and
GABA production may inform dietary interventions to modulate this neurotransmitter in
vivo.
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CHAPTER 2
METHODS & MATERIALS

2.1 Bacterial Propagation
37 strains of Bifidobacterium spp. and Lactobacillus spp. were screened for their
ability to produce GABA. A list of strains can be found in Table 3.1. Bacteria was routinely
propagated in De Mann Rogosa Sharpe (MRS, BD Difco, FisherScientific, Hampshire,
NH) medium supplemented with 0.05% L-cysteine hydrochloride (Acros Organics, UK)
at 37 C under anaerobic conditions (Coy Laboratory Products, Grass Lake, MI) for 24-48
hours. A set of experiments for observation of GABA production were conducted as
follows: i) overnight cultures were inoculated into MRS medium supplemented with 3%
(wt/v, 30 mg/ml) monosodium glutamate (MSG, Sigma-Aldrich, St. Louis, MO) for 72
hours. ii) overnight cultures of GABA producers were inoculated into MRS medium
supplemented with 1%, 2%, and 3% MSG (wt/v, 10 mg/ml, 20 mg/ml, 30 mg/ml). iii)
overnight cultures were inoculated into modified MRS (mMRS, without acetate and
glucose) medium with 1% (wt/v) MSG and either lactose (FisherScientific) or
fructooligosaccharides from chicory (Sigma-Aldrich) at 2% (wt/v). 1 ml of vortexed
culture was bead beat at 5.5 m/sec for three 30 s intervals, cooled in ice in between, to
release intracellular glutamate. Each experiment was evaluated in biological triplicates that
were centrifuged at 10,000 rpm for 1 min and cell-free supernatant was stored at -20 C
until used for HPLC analysis.
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2.2 Quantification of bacterial produced GABA
Glutamate and GABA standards prepared in MRS and cell-free supernatants were
derivatized using dansyl chloride according to the procedure outlined in Le Vo et al. 28 to
produce dansyl glutamate and dansyl GABA. The dansyl derivatization method was
adapted because dansyl amino acids can be quantified using a UV detector. To a 2 ml
microcentrifuge tube the following were added: 100 ul of sample cell-free supernatant or
standard, 200 ul of 1 M sodium bicarbonate buffer (pH 9.5), 100 ul of 80 mg/ml dansyl
chloride in acetonitrile and 600 ul of double distilled water. The tube was vortexed and
then incubated for 40 min at 80 C. Following incubation, 100 ul of diluted acetic acid (20
ul/1 ml dd water) was added to the microcentrifuge tube to stop the reaction. The
derivatized solution was vortexed then centrifuged at 10,000 rpm for 5 min.
Supernatant from the derivatization process was filtered through a 0.2 m Minisart
RC 4 filter (Sartorius, FisherScientific) and analyzed using an Agilent 1260 Infinity HPLC
(Agilent Technologies, Santa Clara, CA) system equipped with a UV detector. Separation
was carried out using a Waters Corp XBridge BEH C18 Column (130 Å, 5 m, 4.6 x 250
mm) with a XBridge BEH C18 VanGuard Cartridge (130 Å, 5 m, 3.9 x 5 mm) and holder
at 30 C with the detector temperature maintained at 30 C. As described by Wu and Shah43
two mobile phases, A (30 mM ammonium acetate in HPLC water, Fisher Chemical) and
B (100% acetonitrile, Optima, FisherScientific) were used for separation. The column was
eluted with a modified linear gradient of 6 to 10% B over 0 to 5 min, 10 to 18% B over 5
to 7 min, 18 to 22% B over 7 to 15 min, 22 to 26% B over 15 to 18.5 min, 26 to 28.5% B
over 18.5 to 22.5 min, 28.5 to 30% B over 22.5 to 24 min, 30 to 32% B over 24 to 27.5 min,
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32 to 40% B over 27.5 to 30 min, 40 to 55% B over 30 to 40 min, 55 to 50% B over 40 to
45 min, 50 to 6% B over 45 to 48 min and held at 6% B for 2 min at a flow rate of 1 ml/min
for a total of 50 mins. Each sample was injected twice with an injection volume of 20 ul
and detected at an absorbance of 275 nm. Glutamate eluted from the column first at 14.5
mins and GABA eluted second at 25 mins. Glutamate and GABA standard curves were
both prepared as 10 mM, 50 mM, 100 mM and 150 mM solutions.

2.3 Minimum inhibitory concentrations (MICs) of MSG and GABA
MSG (99%>) and GABA (99%>) were both obtained from Sigma-Aldrich in
powder form and kept at room temperature until use. The in vitro antibacterial activities of
both compounds were evaluated against B. adolescentis JCM 1251 and B. adolescentis
JCM 15918, both GABA producers. Preliminary MICs of MSG and GABA against the
strains above were determined by twofold serial microdilutions in MRS medium, adapted
from the procedure outlined in Gunes et al.44. Preliminary results revealed a more narrow
range of concentrations were required to elucidate accurate MICs for MSG and GABA.
The solutions of MSG in MRS ranged from per ml 101.5 mg, 93.0 mg, 84.6 mg, 80.3 mg,
76.1 mg, 71.9 mg, 67.6 mg, 59.2 mg, 50.7 mg, 33.8 mg and 16.9 mg concentrations. The
solutions of GABA in MRS ranged from per ml 123.7 mg, 103.1 mg, 87.7 mg, 82.5 mg,
77.3 mg, 72.2 mg, 67.0 mg, 61.9 mg, 41.2 mg, 20.6 mg and 10.3 mg concentrations.
Solutions were inoculated with overnight bacterial cultures and distributed into 96-well
microtiter plates. Initial OD600nm absorbance values were read in an automated PowerWave
HT microplate spectrophotometer (BioTek Instruments, Inc. Winooski, VT) placed in
anaerobic chamber before incubation. Plates were incubated in anaerobic conditions at
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37 C for 48 hours and final OD600nm absorbance readings were taken in the microplate
reader.

2.4 Primer design and PCR for detection of GABA-production related genes
Bifidobacterium-specific glutamate decarboxylase (gadB) oligonucleotide primers
were constructed using gadB nucleotide sequences from B. adolescentis, B. angulatum,
and B. dentium strains. Sequences were collected using the NCBI/BLAST program
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) and aligned using clustalX. Primers were
synthesized by Invitrogen (ThermoFisher).

The primers

used were Gad2_F

(TGCTGGGAGAAGTTCTGCAACTA) and Gad2_R (GATGGCSACSACGCCGAT
GGTGTT), 5 -3 . PCR

as performed

ith DreamTaq Green Master Mi

(2X,

ThermoFisher) with DNA concentrations ranging between 10-20 ng/ul per 12.5 ul
reactions in a thermocycler (Veriti, Applied Biosystems, Foster City, CA). The cycling
conditions for PCR amplifications of gadB genes were as follows: 95 C for 3 min; 25
cycles of 95 C for 30 s, 55 C for 30 s, 72 C for 1 min; 72 C for 7 mins. PCR products
were run with a 1 kb DNA latter in a 2% agarose gel at 60 volts for 60 to 90 mins and the
presence of PCR product was visualized in the GelDoc-It Imaging System (UVP, Analytik
Jena, Germany).

2.5 Statistical analysis
Metabolite concentrations were subjected to two-way analysis of variance
(ANOVA) and T ke s significant difference test for m ltiple comparisons of strains.
Bacterial growth values were subjected to one- a ANOVA and T ke s significant
difference test for multiple comparisons of strains within a treatment.
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CHAPTER 3
RESULTS

3.1 Bifidobacterium GABA production is strain-dependent and glutamate
concentration-dependent.
Production of GABA in MRS supplemented with 3% glutamate (wt/v) after 72
hours of fermentation was quantified by HPLC in cell-free supernatants. Among the
Lactobacillus spp. tested (Table 3.1), only Lactobacillus brevis NRRL-B4527T produced a
detectable concentration of GABA (76.08 12.28 mM) and served as a positive control for
the screening purposes until a GABA-producing bifidobacteria was identified.
Table 3.1 Bifidobacterium and Lactobacillus strains screened in this studya
Lactobacillus spp. & Bifidobacterium
spp.
L. brevis

Strain

Contains
gadB
+

Contains
gadC
+

Produces
GABA
+

L. johnsonii

ATCC 33200

-

-

-

L. pentosus

NRRL-B227

-

-

-

L. plantarum

ATCC 14917T

+

+

-

ATCC BAA-793

-

-

-

L. reuteri

NRRL-B14121

-

-

-

B. adolescentis

JCM 1251

+

+

+

JCM 1275T

-

-

-

JCM 15918

+

+

+

JCM 7045

+

+

+

JCM 7046

-

-

-

JCM 1252

+

+

+

JCM 7096T

+

+

+

B. animalis subsp. lactis

UMA 905039

-

-

-

B. bifidum

JCM 1254

-

-

-

B. breve

JCM 7019

-

-

-

B. callitrichos

JCM 17296T

-

-

-

B. catenulatum subsp. kashiwanohense

JCM 15439T

-

-

-

B. dentium

JCM 1195T

+

+

+

JCM 7135

+

+

+

B. angulatum

NRRL-B4527T
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B. longum subsp. infantis

UMA 272

-

-

-

UMA 298

-

-

-

UMA 299

-

-

-

UMA 300

-

-

-

UMA 301

-

-

-

UMA 302

-

-

-

ATCC 15707

-

-

-

CECT 7894

-

-

-

B. longum subsp. suillium

JCM 19995T

-

-

-

B. longum subsp. suis

UMA 391

-

-

-

UMA 399

-

-

-

JCM 8219T

+

+

-

JCM 8220

-

-

-

B. moukalabense

JCM 18751T

+

+

+

B. ruminantium

JCM 8221

-

-

-

JCM 8222T

+

+

-

JCM 12489T

-

-

-

B. longum subsp. longum

B. merycicum

B. scardovii
a

NRRL- Agricultural Research Service Culture Collection; ATCC- American Type

Culture Collection; JCM- the Japanese Collection of Microorganism; University of
Massachusetts Amherst Culture Collection
TDenotes

type strain

Following Lactobacillus spp. screening, 31 strains of Bifidobacterium spp. were
screened for GABA production (Table 3.1). 8 strains of bifidobacteria belonging to 4
species (3 B. adolescentis, 2 B. angulatum, 2 B. dentium and 1 B. moukalabense) produced
GABA. Each strain produced a different concentration of GABA, regardless of species. B.
adolescentis strains had absolute GABA concentrations ranging from 6.70 1.98 mM (B.
adolescentis JCM 1251) to 38.65 11.94 mM (B. adolescentis JCM 15918), B. angulatum
strains had absolute GABA concentrations ranging from 24.38 0.71 mM (B. angulatum
JCM 7096) to 90.98 4.61 mM (B. angulatum JCM 1252) and B. dentium strains had
absolute GABA concentrations ranging from 44.68 7.70 mM (B. dentium JCM 7135) to
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54.47 4.58 mM (B. dentium JCM 1195). B. moukalabense JCM 18751 produced
92.63 8.53 mM of GABA (Table 3.2).
Table 3.2 GABA-producing Lactobacillus spp. and Bifidobacterium spp.
Species

Strain

L. brevis

NRRL-B4527T

B. adolescentis

JCM 1251

6.70±1.98

JCM 15918

38.65±11.94

JCM 7045

25.63±2.78

JCM 1252

90.98±4.61

JCM 7096T

24.38±0.71

JCM 1195T

54.47±4.58

JCM 7135

44.68±7.70

JCM 18751T

92.63±8.53

B. angulatum
B. dentium
B. moukalabense

GABA concentration (mM)
76.08±12.28

Table 3.2 contains the absolute values of average final GABA concentrations of
biological triplicates with the standard error of the mean.
To produce GABA, bifidobacteria must possess a gadB gene that encodes for a
glutamate decarboxylase. PCR was performed with bifidobacteria-specific gadB primers
on GABA-producing bifidobacteria. All 8 GABA-producing bifidobacteria were PCR
positive for gadB (Table 3.3). Additional strains that did not produce GABA were also
tested for the presence of gadB. B. adolescentis JCM 1275, the species type strain, was
tested via PCR because three strains of B. adolescentis were gadB positive and produced
GABA. B. adolescentis JCM 1275 did not produce GABA and was PCR negative for gadB.
B. merycicum JCM 8219 and B. ruminantium JCM 8222 were identified through BLASTp
to possess gadB, however these strains did not produce GABA. PCR was performed on B.
merycicum JCM 8219 and B. ruminantium JCM 8222 to confirm the presence of gadB in
their genome, however the results are to be determined.
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Table 3.3 gadB PCR screened bifidobacteria
Bifidobacterium spp.

Strain

B. adolescentis

JCM 1251
JCM 1275T
JCM 15918
JCM 7045
JCM 1252
JCM 7096T
JCM 1195T
JCM 7135
JCM 8219T
JCM 18751T
JCM 8222T

B. angulatum
B. dentium
B. merycicum
B. moukalabense
B. ruminantium

gadB PCR

Produces GABA

+
+
+
+
+
+
+
TBD
+
TBD

+
+
+
+
+
+
+
+
-

Table 3.3 contains the results of bifidobacteria-specific gadB PCR. TBD is to be
determined. PCR was performed on B. merycicum and B. ruminantium, but results were
not identified via gel electrophoresis because of Covid-related closures.
Absolute GABA concentrations post-fermentation of different starting glutamate
concentrations were quantified by HPLC in cell-free supernatants from the 8 GABA
producing bifidobacteria. The starting concentrations of glutamate were 1%, 2% or 3%
(wt/v). For most of the tested bifidobacteria GABA production was not significantly
different from one concentration of glutamate to another (p>0.05). For B. angulatum JCM
1252 and B. moukalabense absolute GABA concentrations significantly increased
(p<0.0001) when the starting glutamate concentration increased from 1% to 2%, however
when starting glutamate concentrations increased from 2% to 3% absolute GABA
concentrations were not significantly different (p>0.05). This indicates that maximum
GABA production is dependent on the concentration of glutamate available, but there is a
limit to how much GABA the organism can produce.
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Figure 3.1 GABA production varies with starting glutamate concentrations
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Figure 3.1 represents absolute GABA concentrations of B. adolescentis JCM 1251,
B. adolescentis JCM 15918, B. adolescentis JCM 7045, B. angulatum JCM 1252, B.
angulatum JCM 7096, B. dentium JCM 1195, B. dentium JCM 7135 and B. moukalabense
JCM 18751 after fermentation in (A) 1% (wt/v, 60 mM), (B) 2% (118 mM), or (C) 3%
MSG (177 mM). Colored bars represent different Bifidobacterium spp. (Purple: B.
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adolescentis; Pink: B. angulatum; Blue: B. dentium; Red: B. moukalabense) and the
average final GABA concentration of biological triplicates. Error bars show the standard
error of the mean. Significant differences among the GABA production of strains on each
glutamate concentration are computed using two-way ANOVA with significance at
**p<0.01, ***p<0.001, ****p<0.0001.
GABA production was not consistent amongst Bifidobacterium spp. In 1%
glutamate (wt/v) B. adolescentis JCM 1251 and B. adolescentis JCM 7045 produced
significantly less (p<0.01) GABA (1.50 1.69 mM and 14.00 2.79 mM, respectively) than
B. adolescentis JCM 15918 (43.95 0.86 mM). This trend was also observed in the B.
angulatum strains. The absolute concentration of GABA produced in 1% glutamate (wt/v)
by B. angulatum JCM 1252 (46.36 2.77 mM) was significantly more (p<0.01) than B.
angulatum JCM 7096 (17.33 1.16 mM, Fig. 3.1A). For all glutamate concentrations (1%,
2% and 3% wt/v) B. angulatum JCM 1252 produced significantly more glutamate than B.
angulatum JCM 7096 (p<0.01, Fig. 3.1). These results indicate GABA production is straindependent, not species-dependent.

3.2 MICS of MSG and GABA
Table 3.4 MIC values of GABA and MSG
Strain

GABA MIC (mg/ml)

MSG MIC (mg/ml)

103.1
82.5

84.6
67.6

B. adolescentis JCM 1251
B. adolescentis JCM 15918

MICs were performed to determine the antibacterial effects of GABA and MSG on
B. adolescentis JCM 1251 and B. adolescentis JCM 15918. MIC values can be found in
Table 3.4. Both compounds exerted antibacterial effects on the tested strains. GABA
inhibited growth for B. adolescentis JCM 1251 at a concentration of 103.1 mg/ml (1 M)
13

and inhibited growth for B. adolescentis JCM 15918 at a concentration of 82.5 mg/ml (800
mM). MSG inhibited growth for B. adolescentis JCM 1251 at a concentration of 84.6
mg/ml (500 mM) and inhibited growth for B. adolescentis JCM 15918 at a concentration
of 67.6 mg/ml (400 mM).

3.3 Bifidobacterial GABA production varies with carbohydrate source
Screening for GABA production utilized glucose in MRS as a carbohydrate source.
To investigate if carbohydrate source modulated GABA production cell-free supernatants
of 8 GABA-producing bifidobacteria grown in different carbohydrates sources were
quantified by HPLC. All organisms were grown with a starting concentration of glutamate
at 1% (wt/v). Carbohydrate sources investigated were glucose (2% wt/v), lactose (2% wt/v)
or FOS (2% wt/v).
Glucose-mediated

GABA

production

had

the

lowest

absolute

GABA

concentrations of all tested sugars (1.50 1.69 mM to 48.22 5.62 mM). B. adolescentis
JCM 1251, B. adolescentis JCM 7045, B. angulatum JCM 7096, and B. dentium JCM 7135
had glutamate present in the media post-fermentation, however the sum of remaining
glutamate and GABA produced did not equal the starting glutamate concentration of 60
mM (1% wt/v). For example, B. angulatum JCM 7096 had 6.94 0.83 mM of glutamate
remaining and produced 17.33 1.16 mM of GABA. For all tested bifidobacteria,
glutamate to GABA conversion was not 1:1 post-glucose fermentation (Fig. 3.2A),
indicating glutamate is being consumed by those organisms for purposes other than GABA
production. In general, absolute GABA concentrations were lower during glucose
fermentation, which could be due to bifidobacterial preference for other sugars.
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Figure 3.2 Absolute glutamate and GABA concentrations following fermentation of
different carbohydrate sources
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Figure 3.2 represents the absolute glutamate and GABA concentrations of B.
adolescentis JCM 1251, B. adolescentis JCM 15918, B. adolescentis JCM 7045, B.
angulatum JCM 1252, B. angulatum JCM 7096, B. dentium JCM 1195, B. dentium JCM
7135 and B. moukalabense JCM 18751 after fermentation on various sole carbon sources.
Shown are GABA and glutamate concentrations after fermentation of (A) glucose (B)
lactose or (C) FOS. Dotted lines represent the starting concentration of glutamate (1% wt/v,
60 mM) before fermentation. Bars represent the average final glutamate or GABA
concentration of biological triplicates and error bars show the standard error of the mean.
Absolute GABA concentrations during lactose fermentation were significantly
different (p<0.05) from GABA concentrations during glucose fermentation for all tested
strains except B. angulatum JCM 7096 and B. dentium JCM 1195. Almost every strain,
except for B. angulatum JCM 7096, utilized all 60 mM of glutamate to produce 60 mM of
GABA (Fig. 3.2B) during lactose fermentation. B. angulatum JCM 7096 had postfermentation glutamate and GABA concentrations (33.12 2.43 mM glutamate and
7.71 0.61 mM GABA) that did not amount to the starting concentration of glutamate (60
mM, 1% wt/v). B. adolescentis JCM 1251 and B. adolescentis JCM 15918 both produced
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an excess of GABA (76.77 7.41 mM and 76.31 7.10 mM, respectively) while consuming
all provided glutamate. This indicates intracellular production of glutamate was increased
during lactose fermentation, which allowed GABA concentrations to exceed 60 mM. Based
on these results, lactose might be utilized as the primary carbohydrate source for maximum
GABA production.
Previously published B. adolescentis, B. angulatum and B. dentium strains had
demonstrated growth on plant oligosaccharides, including FOS6,9,40,41. To modulate GABA
production with plant oligosaccharides, all 8 GABA-producing bifidobacteria strains were
propagated with 2% (wt/v) FOS and 1% (wt/v) glutamate for 72 hours. Growth was
variable on FOS (Fig. 3.3), especially among B. adolescentis strains. B. adolescentis JCM
7045 grew significantly more on FOS than B. adolescentis JCM 1251 and B. adolescentis
JCM 15918 (p<0.001).
Figure 3.3 Bacterial growth after fermentation of fructooligosaccharides
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Figure 3.3 represents the growth of B. adolescentis JCM 1251, B. adolescentis JCM
15918, B. adolescentis JCM 7045, B. angulatum JCM 1252, B. angulatum JCM 7096, B.
dentium JCM 1195, B. dentium JCM 7135 and B. moukalabense JCM 18751 on FOS as a
sole carbon source. Colored bars represent different Bifidobacterium spp. (Purple: B.
adolescentis; Pink: B. angulatum; Blue: B. dentium; Red: B. moukalabense) and the
average final OD600 growth value of biological triplicates. Error bars show the standard
error of the mean. Significant differences among the growth profiles of strains on FOS are
computed using one-way ANOVA with significance at ***p<0.001 and ****p<0.0001.
Regardless of growth all tested strains produced GABA or glutamate, except B.
moukalabense who grew on FOS (OD600nm 0.73±0.09), but did not produce GABA.
Glutamate concentrations increased in B. dentium JCM 1195, B. dentium JCM 7135 and B.
adolescentis JCM 1251, however these organisms did not produce detectable
concentrations of GABA (Fig. 3.2C). B. adolescentis JCM 15918 and B. angulatum JCM
1252 both consumed all present glutamate and produced excess concentrations of GABA
(69.91 1.78 mM and 66.76 5.64 mM, respectively), indicating they were able to utilize
FOS and increase intracellular glutamate production. In total, only 4 strains produced
GABA on FOS, including B. adolescentis JCM 15918, B. angulatum JCM 1252, B.
adolescentis 7045 (49.22 1.23 mM GABA), and B. angulatum JCM 7096 (21.23 1.95
mM GABA). Although B. moukalabense produced the highest absolute GABA
concentrations during glucose and lactose fermentation, during FOS fermentation it did not
produce detectable GABA and had decreased glutamate concentration (47.86 2.63 mM)
from the starting concentration of 60 mM (1% wt/v). Not only can these organisms grow
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on FOS, but these results also indicate that FOS modulates GABA and glutamate
production.
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CHAPTER 4
DISCUSSION & CONCLUSION

4.1 Discussion
Bifidobacteria are important members of the gut microbiome as they ferment hostindigestible oligosaccharides and produce beneficial metabolites, including SCFAs and
amino acids42,45,46. GABA, a non-protein amino acid and the primary inhibitory
neurotransmitter of the CNS, is produced by some Bifidobacterium spp. To produce
GABA, the bifidobacterial chromosome must encode a glutamate decarboxylase, which
synthesizes GABA from glutamate. Previously published GABA-producing bifidobacteria
include strains of B. adolescentis, B. angulatum, B. dentium, and B. longum subsp.
infantis30,38,39, however additional species were identified through BLASTp of a gadB
amino acid sequence from B. adolescentis BBMN2347. The additional bifidobacteria we
identified through BLASTp were strains of B. merycicum, B. moukalabense and B.
ruminantium.
In this study, 33 strains of bifidobacteria were screened for the ability to produce
GABA. 20 strains were from species that i) had published GABA-producing strains or ii)
had strains identified through BLASTp of gadB. We have identified 8 GABA-producing
strains through our screening conditions (Table 3.2). Strains of B. merycicum and B.
ruminantium used in this study were identified to encode gadB through BLASTp, however
neither of these species had GABA-producing strains. Although glutamate was present in
the growth media and the genomes of these strains encoded gadB, GABA was not
produced. Under these experimental conditions, we cannot determine a direct relationship
between GABA production and the presence of gadB in the genome.
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We determined that presence of gadB in the genome is strain-dependent, not
species-dependent. This became apparent when we analyzed gadB through BLASTp. A B.
longum subsp. infantis strain had been published to produce GABA39 but did not appear in
the BLASTp results. We screened six strains of B. longum subsp. infantis for GABA
production, all which failed to produce detectable levels of GABA, and did not have gadB
in their genomes. This point is further validated by the results of the five B. adolescentis
strains screened for GABA production. A multitude of B. adolescentis strains were
identified through BLASTp of gadB, but only three of our tested strains produced GABA.
B. adolescentis JCM 1275T, the type strain, did not produce GABA. Bifidobacteriumspecific gadB PCR was performed on all of the B. adolescentis strains, and gadB was
confirmed in only the GABA-producing B. adolescentis strains (JCM 1251, JCM 15918
and JCM 7045).
The primary growth media for bifidobacteria is MRS with 2% glucose (wt/v) as the
sole carbohydrate source. To investigate if carbohydrate source modulated GABA
production GABA-producing bifidobacteria were propagated in mMRS with lactose (2%
wt/v) as the sole carbon source and supplemented MSG (1% wt/v). Lactose-mediated
GABA production was significantly higher (p<0.05) than glucose-mediated GABA
production for most of the GABA-producing bifidobacteria (excluding B. angulatum JCM
7096 and B. dentium JCM 1195). This phenomenon could be caused by a metabolic
preference of lactose over glucose by the bifidobacteria48-50. The metabolic preference of
lactose could also explain the absolute GABA concentrations of B. adolescentis JCM 1251
and B. adolescentis JCM 15918 exceeding 60 mM (the starting concentration of
glutamate). Based on these results, we can conclude the metabolism of lactose by B.
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adolescentis JCM 1251 and B. adolescentis JCM 15918 increased intracellular glutamate
concentrations, which led to an increase in GABA concentrations past the provided
concentration of glutamate. Glutamate is the primary excitatory neurotransmitter of the
central nervous system and precursor to GABA. It functions as oxidative fuel for the
intestine, as it can be synthesized into alpha-ketoglutarate and utilized in the tricarboxylic
acid (TCA) cycle51.
Host-indigestible oligosaccharides are common carbohydrate sources in the small
intestine5,11,52,53. In order to metabolize oligosaccharides, bifidobacteria have adapted
various enzymes that cleave oligosaccharides into monosaccharides, which can be further
metabolized for energy12. To investigate the relationship between oligosaccharide
consumption and GABA production GABA-producing bifidobacteria were propagated in
mMRS with FOS (2% wt/v) as the sole carbon source and supplemented MSG (1% wt/v).
Only one GABA producer, B. adolescentis JCM 1251, failed to grow on FOS, indicating a
shift in physiology. As hypothesized, fermentation of FOS modulated glutamate and
GABA production. Absolute concentrations of glutamate increased for B. adolescentis
JCM 1251, B. dentium JCM 1195 and B. dentium JCM 7135, but no detectable GABA was
measured for these organisms. B. adolescentis JCM 15918, B. adolescentis JCM 7045 and
B. angulatum JCM 1252 produced significantly more (p<0.01) GABA during fermentation
of FOS compared to fermentation of glucose. Absolute GABA concentrations of B.
adolescentis JCM 15918 and B. angulatum JCM 1252 exceeded 60 mM (the starting
concentration of glutamate), indicating FOS metabolism increased intracellular glutamate
concentrations. B. angulatum JCM 7096 did not produce a significantly different
concentration of GABA during FOS fermentation compared to glucose and lactose
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fermentation. These results indicate FOS fermentation induced a shift in glutamate
production and altered expression of gadB. B. moukalabense grew on FOS, but did not
produce GABA during FOS fermentation. Absolute glutamate concentrations decreased
following FOS fermentation, indicating B. moukalabense utilized glutamate for other
metabolic processes. Glutamate has other metabolic fates and can be synthesized into
glutamine or proline42 if it is not irreversibly decarboxylated by GadB.
One phenomenon that was consistent across all carbohydrate sources was the
production of GABA in the presence of glutamate. In our study GABA was not produced
by bifidobacteria unless extracellular glutamate was present. This phenomenon was
observed with glutamate production as well; excess glutamate was only observed if
glutamate was already present in the extracellular environment. When B. adolescentis JCM
1251 and B. adolescentis JCM 15918 fermented lactose supplemented with MSG (1% wt/v,
60 mM), GABA concentrations exceeded 60 mM, indicating intracellular glutamate
production had been induced by lactose fermentation. This was not observed when B.
adolescentis JCM 1251 and B. adolescentis JCM 15918 fermented lactose without added
glutamate. Neither glutamate nor GABA were detected following fermentation of lactose
alone. We observed this in all tested organisms fermented in all carbohydrate sources. It is
unclear why this phenomenon is occurring, but glutamate is clearly exerting a physiological
effect on the bifidobacteria.
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4.2 Conclusion
Among the 33 bifidobacterial strains tested, only 8 strains, B. adolescentis JCM
1251, B. adolescentis JCM 15918, B. adolescentis JCM 7045, B. angulatum JCM 1252, B.
angulatum JCM 7096, B. dentium JCM 1195, B. dentium JCM 7135, and B. moukalabense
JCM 18751, utilized glutamate to produce GABA. Absolute GABA and glutamate
concentrations were modulated during fermentation of glucose, lactose, and FOS as sole
carbohydrate sources. Glucose fermentation resulted in the lowest absolute GABA
concentrations while lactose fermentation resulted in the highest GABA concentrations.
FOS fermentation modulated GABA and glutamate concentrations. This indicates a shift
in bifidobacterial metabolism and gadB reg lation. Gl tamate s infl ence on
bifidobacterial metabolism should be further investigated, as it increased intracellular
glutamate concentrations only when glutamate was present in the external environment.
Observing gene expression during fermentation of different carbohydrate sources and
glutamate could elucidate the influence these compounds have on bifidobacterial
physiology. The primers developed for this study will be used to detect and quantify gadB
in microbiome samples, allowing us to investigate the relationship between gadB
expression and GABA production in the adult microbiome. Bifidobacterial GABA
production in vivo may be influenced by host consumption of plant oligosaccharides, which
can be further investigated through dietary interventions of humans and animal.
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